Clinical Trial
NCT03328130 Recruiting, Active
Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene
Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression
Disease
Disease type
Retinitis Pigmentosa
Orphan drug recognition
Yes
Patient type
Adult
Children
Inclusion / Exclusion
Funding
industry
Others investigators
ERN EYE member investigating site
HCP : Principal investigators
HCP : Others investigators
Reference Center Rare Diseases ‘Genetic Sensory Diseases’, MAOLYA, Montpellier, France
Adress
Hôpital Gui de ChauliacService Ophtalmologie80, avenue Augustin Fliche 1er étage, bureau 1414
34 295 Montpellier Cedex 5
France